A novel, highly sensitive qPCR assay for the diagnosis of subarachnoid and ventricular neurocysticercosis and for assessing response to treatment.
Treatment of subarachnoid neurocysticercosis is complicated, and assays that can guide treatment are not widely available. The reproducibility and scalability of molecular-based biomarkers would be of great use. The T. solium genome was mined and primers and probes were designed to target repeats with the highest coverage, and the most sensitive, specific, and efficient (TsolR13) was selected for clinical testing. Forty-six plasma samples and 36 CSF samples taken from patients with subarachnoid or ventricular disease were tested by qPCR. The analytic sensitivity of TsolR13 was 97.3% at 240 attograms (ag) of T. solium gDNA, and 100% analytic specificity. The clinical sensitivity in detecting active subarachnoid or ventricular disease in symptomatic patients was 100% in CSF and 81.3% in plasma. The predictive ability to distinguish active from cured disease was better for CSF (94.4% of those cured qPCR was negative) than for plasma (86.7% of those cured were negative). Some subjects also had plasma DNA detectable intermittently years after cure. Overall the test performance was equivalent to T. solium antigen detection. A qPCR test for detection of the highly repetitive Tsol13 sequence has been developed and shown to be highly sensitive and specific for NCC, but also useful as a test of cure in the CSF and for the definitive diagnosis of NCC in the plasma.